Localised disease | Advanced disease | Total (n = 74) | p Value¶ | |||
---|---|---|---|---|---|---|
Stage I (n = 14) | Stage II (n = 27) | Stage III (n = 22) | Stage IV (n = 11) | |||
†Age and follow up period are presented as means (SEM). | ||||||
‡Differences in survival among different stages was statistically significant. | ||||||
§Survival between PlGF ⩾ median and PlGF <median was statistically significant with p = 0.028 by the χ2 test. | ||||||
¶Comparison of localised and advanced disease groups. Sex and survival were analysed using the χ2 method and Fisher’s exact test; age, follow up period, −ΔCT of PlGF, and −ΔCT of VEGF were analysed using the Mann-Whitney test. | ||||||
*p<0.05. | ||||||
Sex | 0.222 | |||||
Male | 6 | 13 | 13 | 7 | 39 | |
Female | 8 | 14 | 9 | 4 | 35 | |
Age (y)† | 74.9 (3.0) | 68.8 (3.1) | 69.6 (2.6) | 62.2 (4.9) | 69.2 (1.7) | 0.181 |
Follow up period (month)† | 24.6 (2.4) | 29.6 (2.1) | 25.4 (2.7) | 20.1 (4.5) | 26.0 (1.4) | 0.150 |
Survival‡* | 0.001 | |||||
Yes | 14 | 24 | 18 | 4 | 60 | |
No | 0 | 3 | 4 | 7 | 14 | |
−ΔCT of PlGF | ||||||
T* | 0.19 (0.32) | 1.11 (0.42) | 0.013 | |||
T/NT ratio* | 0.42 (0.31) | 1.66 (0.30) | 0.009 | |||
−ΔCT of VEGF | ||||||
T | 0.65 (0.23) | 0.91 (0.30) | 0.418 | |||
T/NT ratio | 0.62 (0.28) | 1.07 (0.35) | 0.302 | |||
PlGF ⩾median§ | 5 | 12 | 12 | 9 | 38 | |
Survival* | ||||||
Yes | 28 | |||||
No | 10 | |||||
PlGF <median§ | 9 | 15 | 10 | 2 | 36 | |
Survival* | ||||||
Yes | 32 | |||||
No | 4 |